Long title
An open-label, phase I study to assess the safety of NKR-2 treatment administrated concurrently with 5-azacytidine in tretment-naïve acute myeloid leukemia or myelodysplastic syndrome patients not candidates for intensive therapy (EPITHINK - EPIgenetic drug tretment and THerapeutic Immunotherapy with NKR-2)
Date receipt dossier
EU record number
CYAD-N2T-006
EudraCT number
2018-000745-39
Company / Sponsor
Celyad
Phase
I
Treated organism
Humans
Indication category
Cancer therapy
Disease
Myelodysplasic syndrome or acute myeloid leukemia
Therapeutic approach
Immunotherapy
Genetic modification
NKG2D-chimeric antigen receptor
Method of transfer of nucleic acid of interest
Moloney Murine Leukemia Virus
Administered biological material
Autologous T cells retrovirally transduced with a chimeric antigen receptor based on the NKG2D receptor
Route of administration
Intravenous
Locations in Belgium
CHU Liège, Universitair ziekenhuis Antwerpen, Cliniques Universitaires Saint-Luc, AZ Sint-Jan Brugge Oostende
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
NKR-2